Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation.

van Maren WW, Nierkens S, Toonen LW, Bolscher JM, Sutmuller RP, Adema GJ.

BMC Immunol. 2011 Mar 24;12:23. doi: 10.1186/1471-2172-12-23.


Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.

Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ.

Clin Cancer Res. 2010 Oct 15;16(20):5067-78. doi: 10.1158/1078-0432.CCR-10-1757. Epub 2010 Aug 24.


TLR ligands in the local treatment of established intracerebral murine gliomas.

Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ.

J Immunol. 2008 Nov 15;181(10):6720-9.


In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.

Nierkens S, den Brok MH, Sutmuller RP, Grauer OM, Bennink E, Morgan ME, Figdor CG, Ruers TJ, Adema GJ.

Cancer Res. 2008 Jul 1;68(13):5390-6. doi: 10.1158/0008-5472.CAN-07-6023. Erratum in: Cancer Res. 2008 Aug 15;68(16):6859.


Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.

Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, Nierkens S, Adema GJ.

Int J Cancer. 2008 Apr 15;122(8):1794-802.


CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.

Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ.

Int J Cancer. 2007 Jul 1;121(1):95-105.


Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ.

Br J Cancer. 2006 Oct 9;95(7):896-905. Epub 2006 Sep 5.


Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, Ruers TJ, Adema GJ.

Cancer Res. 2006 Jul 15;66(14):7285-92.


Toll-like receptors on regulatory T cells: expanding immune regulation.

Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ.

Trends Immunol. 2006 Aug;27(8):387-93. Epub 2006 Jun 30. Review.


Toll-like receptor 2 controls expansion and function of regulatory T cells.

Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, Joosten LA, Akira S, Netea MG, Adema GJ.

J Clin Invest. 2006 Feb;116(2):485-94. Epub 2006 Jan 19.


From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias.

Netea MG, Van der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ.

Antimicrob Agents Chemother. 2005 Oct;49(10):3991-6. Review. No abstract available.


CD25+ regulatory cells from HLA-DQ8 transgenic mice are capable of modulating collagen-induced arthritis.

Morgan ME, Witteveen HJ, Sutmuller RP, de Vries RR, Toes RE.

Hum Immunol. 2004 Nov;65(11):1319-27.


Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity.

Wansink DG, Peters W, Schaafsma I, Sutmuller RP, Oerlemans F, Adema GJ, Wieringa B, van der Zee CE, Hendriks W.

Physiol Genomics. 2004 Sep 16;19(1):50-60. Epub 2004 Jun 29.


In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ.

Cancer Res. 2004 Jun 1;64(11):4024-9.


Revival of the regulatory T cell: new targets for drug development.

Sutmuller RP, Offringa R, Melief CJ.

Drug Discov Today. 2004 Apr 1;9(7):310-6. Review.


CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.

Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, de Vries RR, Toes RE.

Arthritis Rheum. 2003 May;48(5):1452-60.


Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ.

Cancer Res. 2002 Nov 1;62(21):6187-93.


Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.

Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2001 Nov 15;167(10):5832-7.


Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ.

J Exp Med. 2001 Sep 17;194(6):823-32.


Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.

J Exp Med. 2001 Aug 20;194(4):481-9.


Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R.

J Immunol. 2001 Apr 15;166(8):5236-44.


Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R.

J Immunol. 2000 Dec 15;165(12):7308-15.


Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, Restifo NP.

Cancer Res. 1999 Jun 1;59(11):2536-40.


Functional analysis of the T-cell-restricted protein tyrosine kinase Txk.

Ellis JH, Sutmuller RP, Sims MJ, Cooksley S.

Biochem J. 1998 Oct 15;335 ( Pt 2):277-84.

Supplemental Content

Loading ...
Support Center